DnB Asset Management’s Celldex Therapeutics CLDX Stock Holding History

DnB Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$422K	Sell	11,350 -6,737	-37%	-$218K	﹤0.01%	865
2026 Q1	$574K	Buy	18,087 +1,186	+7%	+$32.3K	﹤0.01%	725
2025 Q4	$459K	Buy	16,901 +3,650	+28%	+$96.1K	﹤0.01%	681
2025 Q3	$343K	Buy	13,251 +951	+8%	+$22K	﹤0.01%	688
2025 Q2	$250K	Sell	12,300 -334	-3%	-$6.5K	﹤0.01%	681
2025 Q1	$229K	Buy	12,634 +2,503	+25%	+$55.9K	﹤0.01%	703
2024 Q4	$256K	Sell	10,131 -38	-0.4%	-$1.03K	﹤0.01%	698
2024 Q3	$346K	Buy	10,169 +2,297	+29%	+$87.5K	﹤0.01%	675
2024 Q2	$292K	Buy	7,872 +2,523	+47%	+$95.2K	﹤0.01%	675
2024 Q1	$224K	Buy	+5,349	New	+$220K	﹤0.01%	692

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DnB Asset Management's CLDX Position: Q2 2026 in Review

DnB Asset Management reduced its Celldex Therapeutics (CLDX) stake by 37% in Q2 2026, selling an estimated $218K and leaving 11,350 shares worth $422K. The position accounts for ﹤0.01% of the portfolio, ranked #865.

DnB Asset Management first reported a position in CLDX in Q1 2024 and has held it in 10 quarters since. The position peaked at $574K in Q1 2026. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

DnB Asset Management held 11,350 shares of Celldex Therapeutics worth $422K as of Q2 2026.
DnB Asset Management sold 6,737 Celldex Therapeutics shares in Q2 2026, an estimated $218K.
Celldex Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #865 holding.
DnB Asset Management first reported a position in Celldex Therapeutics in Q1 2024 and has held it in 10 quarters since.
DnB Asset Management's Celldex Therapeutics position peaked at $574K in Q1 2026.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.